A KD of MAGOH/MAGOHB and the resulting increase in GADD45A expression in cutaneous melanoma could possibly enhance the effect of other cancer therapies whose main mode of action is not to induce DNA damage, such as targeted therapy or immunotherapy. The gene discussed is MAGOHB; the disease is cutaneous melanoma.